KR100973221B1 - 판두라틴 에이 또는 그의 유도체의 신규한 용도 - Google Patents
판두라틴 에이 또는 그의 유도체의 신규한 용도 Download PDFInfo
- Publication number
- KR100973221B1 KR100973221B1 KR1020070086169A KR20070086169A KR100973221B1 KR 100973221 B1 KR100973221 B1 KR 100973221B1 KR 1020070086169 A KR1020070086169 A KR 1020070086169A KR 20070086169 A KR20070086169 A KR 20070086169A KR 100973221 B1 KR100973221 B1 KR 100973221B1
- Authority
- KR
- South Korea
- Prior art keywords
- panduratin
- staphylococcus
- formula
- acne
- derivative
- Prior art date
Links
- LYDZCXVWCFJAKQ-ZFGGDYGUSA-N Panduratin A Chemical compound OC1=CC(OC)=CC(O)=C1C(=O)[C@H]1[C@H](C=2C=CC=CC=2)CC=C(C)[C@H]1CC=C(C)C LYDZCXVWCFJAKQ-ZFGGDYGUSA-N 0.000 title claims abstract description 77
- LYDZCXVWCFJAKQ-UHFFFAOYSA-N nicolaioidesin A Natural products OC1=CC(OC)=CC(O)=C1C(=O)C1C(C=2C=CC=CC=2)CC=C(C)C1CC=C(C)C LYDZCXVWCFJAKQ-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 206010000496 acne Diseases 0.000 claims abstract description 65
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 63
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 60
- -1 panduratin A compound Chemical class 0.000 claims abstract description 41
- 241000186427 Cutibacterium acnes Species 0.000 claims abstract description 39
- 229940055019 propionibacterium acne Drugs 0.000 claims abstract description 39
- 239000000284 extract Substances 0.000 claims abstract description 34
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 244000060701 Kaempferia pandurata Species 0.000 claims abstract description 11
- 235000013412 Kaempferia pandurata Nutrition 0.000 claims abstract description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 26
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 17
- 241000191938 Micrococcus luteus Species 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 8
- 239000004599 antimicrobial Substances 0.000 claims description 7
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 6
- 239000003208 petroleum Substances 0.000 claims description 6
- 241000192041 Micrococcus Species 0.000 claims description 3
- HTRXGEPDTFSKLI-UHFFFAOYSA-N butanoic acid;ethyl acetate Chemical compound CCCC(O)=O.CCOC(C)=O HTRXGEPDTFSKLI-UHFFFAOYSA-N 0.000 claims description 3
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 241000191940 Staphylococcus Species 0.000 abstract description 56
- 244000005700 microbiome Species 0.000 abstract description 27
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 abstract description 25
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 22
- 210000002615 epidermis Anatomy 0.000 abstract description 16
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 15
- 241000192087 Staphylococcus hominis Species 0.000 abstract description 15
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 abstract description 13
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 abstract description 13
- 241001147691 Staphylococcus saprophyticus Species 0.000 abstract description 5
- 229930193739 panduratin Natural products 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 description 62
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
- 239000000203 mixture Substances 0.000 description 40
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 34
- 241000894006 Bacteria Species 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 21
- 239000003755 preservative agent Substances 0.000 description 20
- 239000006071 cream Substances 0.000 description 19
- 239000006210 lotion Substances 0.000 description 19
- 239000003205 fragrance Substances 0.000 description 18
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 18
- 239000008213 purified water Substances 0.000 description 18
- 235000011187 glycerol Nutrition 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 230000002335 preservative effect Effects 0.000 description 16
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 16
- 239000002904 solvent Substances 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 12
- 230000003902 lesion Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 241000192086 Staphylococcus warneri Species 0.000 description 11
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 9
- 229960000541 cetyl alcohol Drugs 0.000 description 9
- YAYNEUUHHLGGAH-UHFFFAOYSA-N 1-chlorododecane Chemical compound CCCCCCCCCCCCCl YAYNEUUHHLGGAH-UHFFFAOYSA-N 0.000 description 8
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 8
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 8
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 8
- 210000003780 hair follicle Anatomy 0.000 description 8
- 239000002480 mineral oil Substances 0.000 description 8
- 235000010446 mineral oil Nutrition 0.000 description 8
- 229910000160 potassium phosphate Inorganic materials 0.000 description 8
- 235000011009 potassium phosphates Nutrition 0.000 description 8
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 241000186429 Propionibacterium Species 0.000 description 4
- 206010037888 Rash pustular Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 239000000287 crude extract Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- 208000029561 pustule Diseases 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 239000004342 Benzoyl peroxide Substances 0.000 description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005100 correlation spectroscopy Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000002072 distortionless enhancement with polarization transfer spectrum Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- ORJDDOBAOGKRJV-CQSZACIVSA-N (2S)-Pinocembrin Natural products C1([C@H]2CC(=O)C3=C(O)C=C(C=C3O2)OC)=CC=CC=C1 ORJDDOBAOGKRJV-CQSZACIVSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- NYSZJNUIVUBQMM-BQYQJAHWSA-N Cardamonin Chemical compound COC1=CC(O)=CC(O)=C1C(=O)\C=C\C1=CC=CC=C1 NYSZJNUIVUBQMM-BQYQJAHWSA-N 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ORJDDOBAOGKRJV-UHFFFAOYSA-N Dihydrotectochrysin Natural products O1C2=CC(OC)=CC(O)=C2C(=O)CC1C1=CC=CC=C1 ORJDDOBAOGKRJV-UHFFFAOYSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000395033 Kaempferia Species 0.000 description 1
- 235000013422 Kaempferia rotunda Nutrition 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 1
- 241000191973 Staphylococcus xylosus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010046461 Urethral pain Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- XAQHXGSHRMHVMU-UHFFFAOYSA-N [S].[S] Chemical compound [S].[S] XAQHXGSHRMHVMU-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- NYSZJNUIVUBQMM-UHFFFAOYSA-N alpinetin chalcone Natural products COC1=CC(O)=CC(O)=C1C(=O)C=CC1=CC=CC=C1 NYSZJNUIVUBQMM-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000002143 fast-atom bombardment mass spectrum Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- LOYXTWZXLWHMBX-VOTSOKGWSA-N pinocembrin chalcone Chemical compound OC1=CC(O)=CC(O)=C1C(=O)\C=C\C1=CC=CC=C1 LOYXTWZXLWHMBX-VOTSOKGWSA-N 0.000 description 1
- ORJDDOBAOGKRJV-AWEZNQCLSA-N pinostrobin Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)OC)=CC=CC=C1 ORJDDOBAOGKRJV-AWEZNQCLSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 229940024473 salicylic acid emollient and protective preparations Drugs 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940037649 staphylococcus haemolyticus Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 208000037911 visceral disease Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
판두라틴에이 화합물의 농도 | |
프로피오니박테리움 아크네스 | 4 |
스태필로코커스 에피더미스 | 4 |
마이크로코코스 루테우스 | 4 |
스태필로코커스 아우레우스 | 4 |
스태필로코커스 와르네리 | 4 |
스태필로코커스 하에모라이티커스 | 4 |
스태필로코커스 자일로서스 | 8 |
스태필로코커스 호미니스 | 2 |
스태필로코커스 사프로피티쿠스 | 4 |
판두라틴에이 유도체의 농도 | |
프로피오니박테리움 아크네스 | 8 |
스태필로코커스 에피더미스 | 8 |
마이크로코코스 루테우스 | 8 |
스태필로코커스 아우레우스 | 4 |
스태필로코커스 와르네리 | 4 |
스태필로코커스 하에모라이티커스 | 8 |
스태필로코커스 자일로서스 | 4 |
스태필로코커스 호미니스 | 4 |
스태필로코커스 사프로피티쿠스 | 4 |
판두라틴에이 화합물의 농도 | |
프로피오니박테리움 아크네스 | 2 |
스태필로코커스 에피더미스 | 2 |
마이크로코코스 루테우스 | 2 |
스태필로코커스 아우레우스 | 2 |
스태필로코커스 와르네리 | 2 |
스태필로코커스 하에모라이티커스 | 2 |
스태필로코커스 자일로서스 | 4 |
스태필로코커스 호미니스 | 2 |
스태필로코커스 사프로피티쿠스 | 2 |
판두라틴에이 유도체의 농도 | |
프로피오니박테리움 아크네스 | 4 |
스태필로코커스 에피더미스 | 4 |
마이크로코코스 루테우스 | 4 |
스태필로코커스 아우레우스 | 4 |
스태필로코커스 와르네리 | 2 |
스태필로코커스 하에모라이티커스 | 8 |
스태필로코커스 자일로서스 | 4 |
스태필로코커스 호미니스 | 2 |
스태필로코커스 사프로피티쿠스 | 2 |
연구시작 전 평균 개수 | 연구 4주후 평균 개수 | P-value | |
면포 | 19.12 | 6.82 | 0.0065 |
구진 | 13.86 | 5.57 | 0.011 |
농포 | 5.78 | 2.41 | 0.033 |
결절 | 0.84 | 0.21 | 0.0208 |
연구시작 전 평균 개수 | 연구 4주후 평균 개수 | P-value | |
면포 | 18.52 | 5.78 | 0.0057 |
구진 | 14.25 | 6.23 | 0.013 |
농포 | 6.27 | 3.24 | 0.035 |
결절 | 0.93 | 0.32 | 0.0318 |
처리온도(℃) | 60 | 70 | 80 | 90 | 100 | 121 |
판두라틴에이를 가한 플레이트의 저지환의 직경(㎜) |
17 | 16 | 17 | 17 | 18 | 17 |
처리온도(℃) | 60 | 70 | 80 | 90 | 100 | 121 |
판두라틴 에이의 유도체를 가한 플레이트의 저지환의 직경(㎜) |
16 | 17 | 17 | 16 | 18 | 17 |
제조예 1 | 제조예 2 | 제조예 3 | 제조예 4 | |
주 요 구 성 성 분 |
판두라틴 에이 1.0% |
판두라틴 에이 0.1% |
판두라틴 에이 0.01% |
판두라틴 에이 0.001% |
글리세린 2.0% | 글리세린 2.0% | 글리세린 2.0% | 글리세린 2.0% | |
프로필렌글리콜 2.0% | 프로필렌글리콜 2.0% | 프로필렌글리콜 2.0% | 프로필렌글리콜 2.0% | |
인산 칼륨 0.1% | 인산 칼륨 0.1% | 인산 칼륨 0.1% | 인산 칼륨 0.1% | |
인산2나트륨 0.05% | 인산2나트륨 0.05% | 인산2나트륨 0.05% | 인산2나트륨 0.05% | |
향료 0.02% | 향료 0.02% | 향료 0.02% | 향료 0.02% | |
에탄올(96%) 50% | 에탄올(96%) 50% | 에탄올(96%) 50% | 에탄올(96%) 50% | |
정제수 잔부 | 정제수 잔부 | 정제수 잔부 | 정제수 잔부 | |
보존료 0.1% | 보존료 0.1% | 보존료 0.1% | 보존료 0.1% |
여드름병원성균 | 시험액 | 생균수(균수/㎖) | |
0시간 | 24시간 | ||
프로피오니박테리움 아크네스 | 제조예 1 | 2.0×105 | 〈1 |
제조예 2 | 2.0×105 | 〈1 | |
제조예 3 | 2.0×105 | 〈2 | |
제조예 4 | 2.0×105 | 2.1×102 | |
판두라틴 에이를 뺀 화장수 | 2.0×105 | 4.2×103 | |
스태필로코커스 에피더미스 | 제조예 1 | 5.4×105 | 〈1 |
제조예 2 | 5.4×105 | 〈1 | |
제조예 3 | 5.4×105 | 〈2 | |
제조예 4 | 5.4×105 | 1.8×102 | |
판두라틴 에이를 뺀 화장수 | 5.4×105 | 3.8×103 | |
마이크로코커스 루테우스 |
제조예 1 | 6.0×105 | 〈1 |
제조예 2 | 6.0×105 | 〈1 | |
제조예 3 | 6.0×105 | 〈3 | |
제조예 4 | 6.0×105 | 2.5×102 | |
판두라틴 에이를 뺀 화장수 | 6.0×105 | 6.2×103 |
제조예 5 | 제조예 6 | 제조예 7 | 제조예 8 | |
주 요 구 성 성 분 |
판두라틴 에이의 유도체 1.0% |
판두라틴 에이의 유도체 0.1% |
판두라틴 에이의 유도체 0.01% |
판두라틴 에이의 유도체 0.001% |
글리세린 2.0% | 글리세린 2.0% | 글리세린 2.0% | 글리세린 2.0% | |
프로필렌글리콜 2.0% | 프로필렌글리콜 2.0% | 프로필렌글리콜 2.0% | 프로필렌글리콜 2.0% | |
인산 칼륨 0.1% | 인산 칼륨 0.1% | 인산 칼륨 0.1% | 인산 칼륨 0.1% | |
인산2나트륨 0.05% | 인산2나트륨 0.05% | 인산2나트륨 0.05% | 인산2나트륨 0.05% | |
향료 0.02% | 향료 0.02% | 향료 0.02% | 향료 0.02% | |
에탄올(96%) 50% | 에탄올(96%) 50% | 에탄올(96%) 50% | 에탄올(96%) 50% | |
정제수 잔부 | 정제수 잔부 | 정제수 잔부 | 정제수 잔부 | |
보존료 0.1% | 보존료 0.1% | 보존료 0.1% | 보존료 0.1% |
여드름병원성균 |
시험액 |
생균수(균수/㎖) | |
0시간 | 24시간 | ||
프로피오니박테리움 아크네스 |
제조예 5 | 2.0×105 | 〈1 |
제조예 6 | 2.0×105 | 〈1 | |
제조예 7 | 2.0×105 | 〈3 | |
제조예 8 | 2.0×105 | 1.7×102 | |
판두라틴 에이의 유도체를 뺀 화장수 | 2.0×105 | 4.8×103 | |
스태필로코커스 에피더미스 |
제조예 5 | 5.4×105 | 〈1 |
제조예 6 | 5.4×105 | 〈1 | |
제조예 7 | 5.4×105 | 〈2 | |
제조예 8 | 5.4×105 | 2.3×102 | |
판두라틴 에이의 유도체를 뺀 화장수 | 5.4×105 | 5.7×103 | |
마이크로코커스 루테우스 |
제조예 5 | 6.0×105 | 〈1 |
제조예 6 | 6.0×105 | 〈1 | |
제조예 7 | 6.0×105 | 〈2 | |
제조예 8 | 6.0×105 | 2.1×102 | |
판두라틴 에이의 유도체를 뺀 화장수 | 6.0×105 | 5.2×103 |
제조예 9 | 제조예 10 | 제조예 11 | 제조예 12 | ||
주 요 구 성 성 분 |
A | 판두라틴 에이 3.0% |
판두라틴 에이 0.1% |
판두라틴 에이 0.01% |
판두라틴 에이 0.001% |
B | 글리세린 2.0% | 글리세린 2.0% | 글리세린 2.0% | 글리세린 2.0% | |
프로필렌글리콜 2.0% | 프로필렌글리콜 2.0% | 프로필렌글리콜 2.0% | 프로필렌글리콜 2.0% | ||
염화 라우릴 설파이드 8.0% | 염화 라우릴 설파이드 8.0% | 염화 라우릴 설파이드 8.0% | 염화 라우릴 설파이드 8.0% | ||
스테아린 5.4% | 스테아린 5.4% | 스테아린 5.4% | 스테아린 5.4% | ||
미네랄 오일 4.5% | 미네랄 오일 4.5% | 미네랄 오일 4.5% | 미네랄 오일 4.5% | ||
C | 향료 0.02% | 향료 0.02% | 향료 0.02% | 향료 0.02% | |
세틸 알코올 6.5% | 세틸 알코올 6.5% | 세틸 알코올 6.5% | 세틸 알코올 6.5% | ||
정제수 잔부 | 정제수 잔부 | 정제수 잔부 | 정제수 잔부 | ||
보존료 0.1% | 보존료 0.1% | 보존료 0.1% | 보존료 0.1% |
여드름병원성균 | 시험액 | 생균수(균수/㎖) | |
0시간 | 24시간 | ||
프로피오니박테리움 아크네스 | 제조예 9 | 2.0×105 | 〈1 |
제조예 10 | 2.0×105 | 〈1 | |
제조예 11 | 2.0×105 | 〈6 | |
제조예 12 | 2.0×105 | 8.4×102 | |
판두라틴 에이를 뺀 크림 | 2.0×105 | 4.1×103 | |
스태필로코커스 에피더미스 | 제조예 9 | 5.4×105 | 〈1 |
제조예 10 | 5.4×105 | 〈1 | |
제조예 11 | 5.4×105 | 〈8 | |
제조예 12 | 5.4×105 | 4.3×102 | |
판두라틴 에이를 뺀 크림 | 5.4×105 | 7.0×103 | |
마이크로코커스 루테우스 |
제조예 9 | 6.0×105 | 〈1 |
제조예 10 | 6.0×105 | 〈1 | |
제조예 11 | 6.0×105 | 〈4 | |
제조예 12 | 6.0×105 | 2.3×102 | |
판두라틴 에이를 뺀 크림 | 6.0×105 | 2.1×103 |
제조예 13 | 제조예 14 | 제조예 15 | 제조예 16 | ||
주 요 구 성 성 분 |
A |
판두라틴 에이의 유도체 3.0% |
판두라틴 에이의 유도체 0.1% |
판두라틴 에이의 유도체 0.01% |
판두라틴 에이의 유도체 0.001% |
글리세린 2.0% | 글리세린 2.0% | 글리세린 2.0% | 글리세린 2.0% | ||
프로필렌글리콜 2.0% | 프로필렌글리콜 2.0% | 프로필렌글리콜 2.0% | 프로필렌글리콜 2.0% | ||
B |
염화 라우릴 설파이드 8.0% | 염화 라우릴 설파이드 8.0% | 염화 라우릴 설파이드 8.0% | 염화 라우릴 설파이드 8.0% | |
스테아린 5.4% | 스테아린 5.4% | 스테아린 5.4% | 스테아린 5.4% | ||
미네랄 오일 4.5% | 미네랄 오일 4.5% | 미네랄 오일 4.5% | 미네랄 오일 4.5% | ||
향료 0.02% | 향료 0.02% | 향료 0.02% | 향료 0.02% | ||
C |
세틸 알코올 6.5% | 세틸 알코올 6.5% | 세틸 알코올 6.5% | 세틸 알코올 6.5% | |
정제수 잔부 | 정제수 잔부 | 정제수 잔부 | 정제수 잔부 | ||
보존료 0.1% | 보존료 0.1% | 보존료 0.1% | 보존료 0.1% |
여드름병원성균 |
시험액 |
생균수(균수/㎖) | |
0시간 | 24시간 | ||
프로피오니박테리움 아크네스 |
제조예 13 | 2.0×105 | 〈1 |
제조예 14 | 2.0×105 | 〈1 | |
제조예 15 | 2.0×105 | 〈7 | |
제조예 16 | 2.0×105 | 7.8×102 | |
판두라틴 에이의 유도체를 뺀 크림 | 2.0×105 | 4.5×103 | |
스태필로코커스 에피더미스 |
제조예 13 | 5.4×105 | 〈1 |
제조예 14 | 5.4×105 | 〈1 | |
제조예 15 | 5.4×105 | 〈6 | |
제조예 16 | 5.4×105 | 3.9×102 | |
판두라틴 에이의 유도체를 뺀 크림 | 5.4×105 | 6.8×103 | |
마이크로코커스 루테우스 |
제조예 13 | 6.0×105 | 〈1 |
제조예 14 | 6.0×105 | 〈1 | |
제조예 15 | 6.0×105 | 〈7 | |
제조예 16 | 6.0×105 | 2.5×102 | |
판두라틴 에이의 유도체를 뺀 크림 | 6.0×105 | 2.3×103 |
연구시작전 평균 개수 | 연구 4주후 평균 개수 | P-value | |
면포 | 19.43 | 5.19 | 0.0081 |
구진 | 17.90 | 6.05 | 0.0027 |
농포 | 5.81 | 2.05 | 0.0225 |
결절 | 0.75 | 0.22 | 0.031 |
연구시작전 평균 개수 | 연구 4주후 평균 개수 | P-value | |
면포 | 18.92 | 4.97 | 0.0075 |
구진 | 18.82 | 7.04 | 0.0031 |
농포 | 6.53 | 3.02 | 0.0232 |
결절 | 0.58 | 0.18 | 0.025 |
Claims (8)
- 삭제
- 카엠페리아 판두라타(Kaempferia pandurata)의 물 또는 C1 ~ C6의 유기용매에 의한 추출물을 유효성분으로 함유하여 프로피오니박테리움 아크네스 또는 마이크로코코스 루테우스에 대해 항균활성을 나타내는 것을 특징으로 하는 항균용 약학적 조성물.
- 제3항에 있어서, 상기 C1 ~ C6의 유기용매는 C1 ~ C6의 알코올, 아세톤(acetone), 에테르(ether), 벤젠(benzene), 클로로포름(chloroform), 에틸아세테이트(ethyl acetate), 메틸렌클로라이드(methylene chloride), 헥산(hexane), 시클로헥산(cyclohexane), 석유에테르(petroleum ether)로 이루어진 군 중에서 선택되는 것임을 특징으로 하는 항균용 약학적 조성물.
- 삭제
- 카엠페리아 판두라타(Kaempferia pandurata)의 물 또는 C1 ~ C6의 유기용매에 의한 추출물을 유효성분으로 함유하여 프로피오니박테리움 아크네스 또는 마이크로코코스 루테우스에 의한 여드름 치료용 약학적 조성물.
- 제7항에 있어서, 상기 C1 ~ C6의 유기용매는 C1 ~ C6의 알코올, 아세톤(acetone), 에테르(ether), 벤젠(benzene), 클로로포름(chloroform), 에틸아세테이트(ethyl acetate), 메틸렌클로라이드(methylene chloride), 헥산(hexane), 시클로헥산(cyclohexane), 석유에테르(petroleum ether)로 이루어진 군 중에서 선택되는 것임을 특징으로 하는 여드름 치료용 약학적 조성물.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20060081372 | 2006-08-25 | ||
KR1020060081372 | 2006-08-25 | ||
KR20060101088 | 2006-10-17 | ||
KR1020060101088 | 2006-10-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080018855A KR20080018855A (ko) | 2008-02-28 |
KR100973221B1 true KR100973221B1 (ko) | 2010-08-02 |
Family
ID=39107002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070086169A KR100973221B1 (ko) | 2006-08-25 | 2007-08-27 | 판두라틴 에이 또는 그의 유도체의 신규한 용도 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100973221B1 (ko) |
WO (1) | WO2008023966A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190131765A (ko) | 2018-05-17 | 2019-11-27 | 이호규 | 핑거루트 추출물의 독성 제거방법 및 이 방법에 의하여 독성이 제거된 핑거루트 추출물을 함유하는 피부 항상성 무독성 화장료 조성물 |
KR20210021747A (ko) | 2019-08-19 | 2021-03-02 | 이호규 | 천연식물 화장품소재 핑거루트의 추출방법 및 그 추출물을 함유하는 피부탄력 화장료 조성물 및 그 제조방법 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101088069B1 (ko) * | 2007-10-17 | 2011-11-29 | (주)뉴트리 | 판두라틴 유도체 또는 이를 함유하는 카엠페리아 판두라타 추출물의 신규한 용도 |
KR20090093477A (ko) * | 2008-02-29 | 2009-09-02 | (주)아모레퍼시픽 | 카엠페리아 판두라타 추출물을 함유한 피부 질환 예방 또는개선을 위한 조성물 |
EP2351559B1 (en) * | 2008-10-09 | 2015-08-12 | Newtree Co., Ltd. | Novel use of panduratin derivative or boesenbergia pandurata extract |
KR101698201B1 (ko) * | 2010-05-20 | 2017-01-19 | (주)뉴트리 | 판두라틴 유도체 또는 보에센베르기아 판두라타 추출물을 포함하는 근육 증가 촉진, 항-피로 및 운동수행능력 향상용 조성물 |
CN113493487B (zh) * | 2021-04-29 | 2022-05-17 | 深圳海创生物科技有限公司 | 一种化合物和组合物及其在制备促进益生菌增殖和/或抑制有害菌生长的产品中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100492034B1 (ko) * | 2002-01-09 | 2005-05-31 | 황재관 | 판두라틴 유도체를 함유하는 충치 및 치주염 예방과치료용 항균제 및 구강 조성물 |
-
2007
- 2007-08-27 WO PCT/KR2007/004109 patent/WO2008023966A1/en active Application Filing
- 2007-08-27 KR KR1020070086169A patent/KR100973221B1/ko active IP Right Grant
Non-Patent Citations (3)
Title |
---|
Food Science and Biotechnology, Vol.14, No.2, pp.286-289 (2005)* |
International Journal of Antimicrobial Agent, Vol.23, pp.377-381 (2004)* |
Phytochemistry, Vol.59 pp.169-173 (2002)* |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190131765A (ko) | 2018-05-17 | 2019-11-27 | 이호규 | 핑거루트 추출물의 독성 제거방법 및 이 방법에 의하여 독성이 제거된 핑거루트 추출물을 함유하는 피부 항상성 무독성 화장료 조성물 |
KR20210021747A (ko) | 2019-08-19 | 2021-03-02 | 이호규 | 천연식물 화장품소재 핑거루트의 추출방법 및 그 추출물을 함유하는 피부탄력 화장료 조성물 및 그 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
KR20080018855A (ko) | 2008-02-28 |
WO2008023966A1 (en) | 2008-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4547388B2 (ja) | リグナン系化合物を利用したニキビ治療方法及び組成物(methodandcompositionfortreatingacneusinglignancompounds) | |
KR100721421B1 (ko) | 항균 및 항진균 활성을 갖는 솔방울 추출물, 및 이를유효성분으로 하는 피부질환 개선용 화장료 조성물 | |
US20200215145A1 (en) | Use of polyphenol containing sugar cane extracts for preventing, improving or treating a skin condition | |
KR100973221B1 (ko) | 판두라틴 에이 또는 그의 유도체의 신규한 용도 | |
KR101135172B1 (ko) | 황백, 어성초, 선학초, 작약 및 감초의 혼합추출물을 유효성분으로 함유하는 여드름 예방, 개선 또는 치료용 조성물 | |
KR102059392B1 (ko) | 정향, 히비스커스, 및 코코넛 추출물을 유효성분으로 포함하는 항균 및 항진균 조성물 | |
KR101419588B1 (ko) | 홍삼 오일을 유효성분으로 함유하는 피부 보습용 조성물 | |
KR102221627B1 (ko) | 붉나무 추출물을 유효성분으로 포함하는 조성물 | |
JP5542145B2 (ja) | イワヤツデ抽出物およびそれから分離した活性成分を含む抗菌性薬学組成物 | |
KR101921050B1 (ko) | 천연 화합물을 포함하는 여드름 개선용 항균 조성물 | |
KR102004468B1 (ko) | 하고초 추출물을 유효성분으로 함유하는 피부 재생 촉진용 조성물 | |
KR20120065034A (ko) | 피부 감염의 예방 및 치료용 조성물 | |
KR20100041258A (ko) | 제이에스원의 신규한 용도 | |
KR20170065187A (ko) | 티트리 잎 복합 추출물을 함유하는 여드름 개선용 화장료 조성물 | |
KR102488864B1 (ko) | 가자 추출물 및 애엽 추출물을 함유하는 피부세균총의 생장 조절 또는 피부 면역 강화용 조성물 | |
KR102416652B1 (ko) | 미세먼지로 인한 피부자극 완화 및 피부 개선용 화장료 조성물 | |
KR102009239B1 (ko) | 자단향 추출물을 유효성분으로 함유하는 피부 재생 촉진용 조성물 | |
KR101323781B1 (ko) | 대량강으로부터 추출한 항균 유효성분을 함유하는 항민감성 피부용 화장료조성물 | |
EP2512495B1 (en) | Process for obtaining a standardised extract of quercetin an 3-o-methylquercetin from flowers of macela (achyrocline satureioides), and cosmetic and pharmaceutical compositions comprising said extract | |
KR20230076873A (ko) | 쑥속 식물 추출물을 유효성분으로 포함하는 피부 로사시아 예방 및 개선용 조성물 | |
KR101175110B1 (ko) | 지누아리 및 비단풀의 혼합추출물을 유효성분으로 하는 헤르페스 바이러스성 피부질환 예방 및 치료용 약학적 조성물 | |
KR20230080174A (ko) | 미성숙 탱자 열매 추출물을 포함하는 항산화, 항염증 및 여드름의 예방 및 치료용 조성물 | |
KR20220161992A (ko) | 차조기 추출물을 포함하는 항산화, 항균, 항염, 또는 항주름용 조성물 | |
KR20210130595A (ko) | 도깨비바늘속 식물 추출물을 유효성분으로 포함하는 민감성 피부용 조성물 | |
KR20240040440A (ko) | 검은지느러미 빙어 추출물 또는 에메랄드 암치 추출물을 유효성분으로 포함하는 항균용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
N231 | Notification of change of applicant | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
E801 | Decision on dismissal of amendment | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090724 Effective date: 20100625 Free format text: TRIAL NUMBER: 2009101006901; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090724 Effective date: 20100625 |
|
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130716 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150710 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160718 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170725 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180725 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190725 Year of fee payment: 10 |